Other Events ·
Nasdaq grants RedHill Biopharma an additional 180 days to regain compliance with the $1.00 minimum bid price requirement
RDHLRedHill Biopharma Ltd.
The Nasdaq Stock Market notified RedHill Biopharma that it has been granted an additional 180 calendar day period, extending until April 5, 2027, to regain compliance with the minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This extension follows a prior notification on April 8, 2026, which cited 30 consecutive business days where the closing bid price of the company's American Depositary Shares (ADSs) fell below the threshold. The initial compliance period was set to expire on October 5, 2026. To regain compliance before the new deadline, the ADS closing bid price must remain at or above $1.00 for a minimum of 10 consecutive business days. The company states it meets all other continued listing requirements and that this notification has no immediate effect on trading under the symbol "RDHL." RedHill Biopharma operates in the biotechnology industry, focusing on the development and commercialization of pharmaceutical products.